Pedal to the metal, Amgen finally has a hot new drug star on its hands — and they have some news
Once you’ve got some buzz going for a potential breakthrough drug, it doesn’t take much more than a hint of progress to get the industry spotlight to swivel back in your direction.
For Amgen $AMGN, where that kind of R&D excitement has been a long time coming, their moment arrived Tuesday evening, when the pharma giant noted that they had registered widening responses for their KRAS drug AMG510, adding tumor responses in colorectal and appendiceal cancer patients after reporting a 50% response rate among a tiny group of non-small cell lung cancer groups at ASCO.
“We have completed enrollment in our monotherapy expansion cohort and are also now enrolling non-small cell lung cancer patients in the PD-1 combination arm,” added R&D chief David Reese in their call with analysts.
There’s more. From Reese:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.